Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 18, 2003, Pages 2989-2992

  Moravcová, Daniela ^a   Kryštof, Vladimír ^b   Havlíček, Libor ^a   Moravec, Jiří ^a   Lenobel, René ^b   Strnad, Miroslav ^b  

^a INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 BROMOBENZYL)AMINO 9 ISOPROPYLPURINE; 6 (2 HYDROXYBENZYL)AMINO 9 ISOPROPYLPURINE; 6 (3 CHLOROANILINO) 9 ISOPROPYLPURINE; 6 (3 HYDROXY 4 METHOXYBENZYL)AMINO 9 ISOPROPYLPURINE; 6 (3 HYDROXYBENZYL)AMINO 9 ISOPROPYLPURINE; 6 (4 HYDROXYBENZYL)AMINO 9 ISOPROPYLPURINE; 6 (ISOPENT 2 EN 1 YLAMINO) 9 ISOPROPYLPURINE; 6 FURFURYLAMINO 9 ISOPROPYLPURINE; 6 PENTYLAMINO 9 ISOPROPYLPURINE; 7 (2 BROMOBENZYL)AMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 (2 HYDROXYBENZYL)AMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 (3 CHLOROANILINO) 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 (3 HYDROXY 4 METHOXYBENZYL)AMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 (3 HYDROXYBENZYL)AMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 (4 HYDROXYBENZYL)AMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 (4 METHOXYBENZYL)AMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 (ISOPENT 2 EN 1 YLAMINO) 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 BENZYLAMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 FURFURYLAMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; 7 PENTYLAMINO 3 ISOPROPYLPYRAZOLO[4,3 D]PYRIMIDINE; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN K 562; DRUG IDENTIFICATION; DRUG SCREENING; INHIBITION KINETICS; REACTION ANALYSIS; SUBSTITUTION REACTION;

EID: 0042011588     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00631-0     Document Type: Article

References (10)

1. Hecht S.M., Bock R.M., Schmitz R.Y., Skoog F., Leonard N.J. Proc. Natl. Acad. Sci. U.S.A. 68:1978;2608.
2. (a) Veselý J., Havlíček L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J., Detivaud L., LeClerc S., Meijer L. Eur. J. Biochem. 224:1994;771.
3. (b) Havlíček L., Hanuš J., Veselý J., LeClerc S., Meijer L., Shaw G., Strnad M. J. Med. Chem. 40:1997;408.
4. (c) Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.H., Lockhart D.J., Schultz P.G. Science. 281:1998;533.
5. Baraldi P.G., Cacciari B., Leoni A., Recanatini M., Roberti M., Rossi M. Farmaco. 46:1991;1337.
6. 4) C, H, N. Methyl 4-amino-5-isopropylpyrazol-3-carboxylate (III).
7. Kelley J.L., Bullock R.M., Krochmal M.P., McLean E.W., Linn J.A., Durcan M.J., Cooper B.R. J. Med. Chem. 40:1997;3207.
8. Otyepka M., Kryštof V., Havlíček L., Siglerová V., Strnad M., Koča J. J. Med. Chem. 43:2000;2506.
9. Franěk F., Havlíček L., Siglerová V., Strnad M., Eckschlager T., Weigl E. Collect. Czech. Chem. Commun. 67:2002;257.
10. Kryštof V., Lenobel R., Havlíček L., Kuzma M., Strnad M. Bioorg. Med. Chem. Lett. 12:2002;3283.